TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Profusa ( (PFSA) ) has shared an announcement.
On July 11, 2025, Profusa announced the completion of its business combination with NorthView Acquisition Corp, marking its transition to a public company. This strategic move is expected to enhance Profusa’s ability to advance its biosensor platform, which aims to improve chronic disease management through real-time biochemical monitoring. The company’s common stock is set to begin trading on Nasdaq under the ticker ‘PFSA’ on July 14, 2025. Additionally, Profusa secured a $9 million convertible promissory note to cover transaction costs and support future working capital needs, with up to $20 million available under the facility.
More about Profusa
Profusa is a commercial stage digital health company based in Berkeley, California, specializing in the development of tissue-integrated sensors for continuous biochemical monitoring. The company aims to provide personalized medical-grade data for personal and clinical use, leveraging its biosensor technology and intelligent data platform.
Average Trading Volume: 755,372
Technical Sentiment Signal: Sell
Current Market Cap: $6.69M
See more insights into PFSA stock on TipRanks’ Stock Analysis page.